Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 16 chart positions in 16 markets.
By chart position
- 🇮🇳IN · Medicine#6410K to 30K
- 🇳🇱NL · Medicine#1541K to 10K
- 🇲🇽MX · Medicine#1971K to 10K
- 🇵🇭PH · Medicine#1930K to 100K
- 🇨🇴CO · Medicine#953K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
15K to 58K🎙 Daily cadence·149 episodes·Last published today - Monthly Reach
Unique listeners across all episodes (30 days)
51K to 193K🇵🇭52%🇮🇳16%🇳🇱5%+13 more - Active Followers
Loyal subscribers who consistently listen
28K to 106K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Talk Liver To Me - Liver Transplantation: Rise of the machines
May 13, 2026
37m 24s
Talk Liver To Me - Spontaneous Bacterial Peritonitis: Time to Rethink the Rules?
Apr 29, 2026
35m 04s
EASL DeepDive: Key Updates in the EASL Clinical Practice Guidelines on extrahepatic Cholangiocarcinoma (eCCA)
Apr 23, 2026
1h 07m 20s
Talk Liver To Me - World Liver Day: Making Lifestyle Change Possible
Apr 15, 2026
34m 30s
EASL DeepDive: Key Changes in the New EASL HBV Guidelines
Apr 9, 2026
1h 16m 17s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5/13/26 |  Talk Liver To Me - Liver Transplantation: Rise of the machines | In this episode, we discuss the first pig-to-human liver xenotransplantation and the breakthroughs behind the revival of xenotransplantation, examining its potential and remaining challenges. We also explore the accelerating field of machine perfusion, clarifying different approaches and reviewing the evidence supporting their role in organ assessment, optimisation, and DCD utilisation. Host: Sarwa Darwish Murad (Erasmus University Rotterdam) Speakers: Jeroen de Jonge (Erasmus University Rott... | 37m 24s | ||||||
| 4/29/26 |  Talk Liver To Me - Spontaneous Bacterial Peritonitis: Time to Rethink the Rules? | Spontaneous bacterial peritonitis (SBP) remains a major complication of cirrhosis - but rising antimicrobial resistance and emerging data are challenging long-standing practices. In this episode, we review current evidence on primary and secondary prophylaxis, resistance patterns, albumin use, and treatment strategies. How should clinicians balance prevention with antimicrobial stewardship? And where might practice need to evolve in 2026? Host: Thomas Marjot (King's College London) Speakers:&... | 35m 04s | ||||||
| 4/23/26 |  EASL DeepDive: Key Updates in the EASL Clinical Practice Guidelines on extrahepatic Cholangiocarcinoma (eCCA) | In this EASL DeepDive webinar, the expert panel presents and explains the key studies behind the latest recommendations included in the EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma. Learning Objectives To identify patients at risk for eCCA, and review the current tools and strategies for its surveillance, diagnosis, staging, and classificationTo define the optimal candidates for resection and liver transplantation, and discuss challenges in the surgic... | 1h 07m 20s | ||||||
| 4/15/26 |  Talk Liver To Me - World Liver Day: Making Lifestyle Change Possible | This episode explores the role of lifestyle in preventing and managing liver disease, including MASLD/MASH. Our experts discuss the impact of diet and physical activity, why lifestyle change can be difficult to start and sustain, and why small, achievable steps can still make a meaningful difference. Host: Cyrielle Caussy Speakers: Kate Hallsworth and Manuel Romero-Gómez This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-07 | 34m 30s | ||||||
| 4/9/26 |  EASL DeepDive: Key Changes in the New EASL HBV Guidelines | In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, published in the "Journal of Hepatology" in 2025. Learning objectives Understand the updated EASL recommendations for initiating and discontinuing antiviral therapy in chronic hepatitis B, including key differences with other HBV guidelines. Participants will be able to identify treatment indications and make informed decisions about when a... | 1h 16m 17s | ||||||
| 4/9/26 |  EASL DeepDive: EASL Clinical Practice Guidelines on the management of autoimmune hepatitis | In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of autoimmune hepatitis, published in the "Journal of Hepatology" in 2025. Learning objectives Select induction and maintenance treatment strategies aimed at achieving complete biochemical responseRecognise and manage disease flares, treatment intolerance, and suboptimal response in autoimmune hepatitisUnderstand tailored approaches to autoimmune hepatitis management in s... | 1h 19m 01s | ||||||
| 4/9/26 |  EASL DeepDive: The Pursuit of a Cure: HCC Management Strategies | Hepatocellular carcinoma (HCC) is responsible for 75% of all primary liver cancers and is the third most prevalent cause of cancer death worldwide, with 900,000 new cases diagnosed each year. Many patients are diagnosed at an advanced stage, making curative treatment difficult. In this DeepDive Webinar, you’ll be guided through the latest advances in hepatocellular carcinoma management, from the rising impact of immunotherapy combinations to evolving approaches in intermediate-stage disease.&... | 1h 15m 02s | ||||||
| 4/1/26 |  Talk Liver To Me - Baveno VIII: The takeaways you shouldn’t miss | In this episode our speakers share their immediate impressions and break down the key highlights shaping the management of portal hypertension and advanced liver disease. What has truly changed in practice? Where was consensus reached and where do controversies remain? Tune in for a clear, practical overview of what you need to know from Baveno VIII. Host: Thomas Marjot Speakers: Mattias Mandorfer and Cristina Ripoll This episode is also available on EASL Campus: https://easlcampus.eu/t... | 37m 19s | ||||||
| 3/18/26 |  Talk Liver To Me - Updated BCLC Guidelines for HCC: Protocolised or Patient-Centred Care? | This episode unpacks the updated BCLC guidelines for hepatocellular carcinoma management. Experts discuss the strengths and limitations of the BCLC model in an era of rapidly evolving systemic therapies and personalised care, sharing real-world examples of when the algorithm helps and when clinical practice diverges. Host: Mattias Mandorfer Speakers: Marco Sanduzzi, Lorenza Rimassa This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-05 | 29m 50s | ||||||
| 3/4/26 |  Talk Liver To Me - When Cure isn’t the only goal: Palliative Care in Advanced Liver Disease | As deaths from advanced chronic liver disease rise, many patients never receive timely palliative care. In this episode, we explore why early, holistic support is essential in advanced liver disease and HCC, and unpack key recommendations from the new EASL Position Paper to help reduce suffering and improve quality of life. Host: Debbie Shawcross Speakers: Patrizia-Künzler-Heule, Sumita Verma This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-04 | 35m 04s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 2/18/26 |  Talk Liver To Me - MetALD in Practice: Does it Change How We Treat Patients? | This episode explores whether MetALD is a meaningful clinical entity or an unnecessary complication. Experts discuss the overlap between metabolic dysfunction and alcohol use, the challenges of applying the MetALD definition in practice, and its impact on classification, guidelines, drug development, and patient care. Host: Thomas Marjot Speakers: Mary Rinella , Aleksander Krag This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-03 | 40m 47s | ||||||
| 2/4/26 |  Talk Liver To Me - From imposter syndrome to influence: Women shaping hepatology | EASL’s Secretary General and Vice Secretary General share an open conversation on the challenges and opportunities for women in hepatology. The episode explores the role of mentorship across career stages and reflects on the journey toward EASL’s first female Secretary General, offering insights on leadership and change in the field. Host: Maja Thiele Speakers: Debbie Shawcross, Ana Lleo This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-02 | 36m 38s | ||||||
| 1/21/26 |  Talk Liver To Me - Hepatology Ward Rounds: East Meets West | In collaboration with the Indian National Association for the Study of the Liver (INASL), hepatologists from South Asia and North America/Europe take listeners inside their liver wards to explore how regional context shapes acute liver care. From admission patterns to alcohol use, infections, DILI, nutrition, and access to transplant, the episode highlights key differences and opportunities for shared learning across regions. This episode is also available on EASL Campus: https://easlcampus.e... | 36m 26s | ||||||
| 12/18/25 | EASL Studio Podcast: Collaborating across disciplines to find the best solution for people living with PBC | This EASL Studio episode brings key insights from the 2025 EASL–AASLD Consensus Conference on Primary Biliary Cholangitis (PBC). Experts explore the use of surrogate endpoints, the challenges in current trial design and regulation, the value of real-world evidence, and how quality-of-life assessment can support future pathways. Moderator: David Jones Speakers: Marco Carbone, Bettina Hansen, and Ana Lleo All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Vide... | 33m 07s | ||||||
| 12/11/25 |  EASL Studio Podcast: What Can Be Done to Safeguard Young Adults from SLD? | How can we protect young adults from steatotic liver disease (SLD)? This episode explores the burden of MASLD, MetALD, and ALD in Europe, the synergistic effects of alcohol and metabolic risk factors, and why the younger population is especially vulnerable. Experts also examine the disparities in risk factors and the role of clinics and policymakers in prevention. Moderator: Shira Zelber Sagi Speakers: Carina Ferreira-Borges (WHO representative) and Zobair Younossi This EASL Studio is support... | 40m 03s | ||||||
| 12/4/25 | EASL Studio Podcast: Decoding AASLD The Liver Meeting: Trends Shaping Hepatology | What were the key takeaways from this year’s AASLD The Liver Meeting? In this episode, experts unpack the most impactful studies, clinical insights, and emerging trends shaping the future of hepatology. From liver cancer breakthroughs to MASLD, ALD, and beyond. Moderator: Debbie Shawcross Speakers: Saul Karpen, Allison Kwong, Mazen Noureddin All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts. | 35m 56s | ||||||
| 11/27/25 | EASL Studio Podcast: Rifaximin for Hepatic Encephalopathy: Balancacing Benefits and Risks in the Era of Antimicrobial Resistance | For World Antimicrobial Awareness Week 2025 (“Act Now: Protect Our Present, Secure Our Future”), this EASL Studio explores the balance between rifaximin’s benefits in hepatic encephalopathy and the global challenge of antimicrobial resistance. Moderator: Debbie Shawcross Speakers: Rajiv Jalan, Vishal Patel, Jonel Trebicka All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts. This EASL Studio is supported by Alfasigma and Norgine.... | 36m 37s | ||||||
| 11/13/25 |  EASL Studio Podcast: Behind the Decision: How Can You Maximize Your Chances of Publication in JHEP Reports? | Ever wondered what happens to your manuscript after submission? In this episode, the JHEP Reports editorial team takes you behind the scenes: from first triage to reviewer selection, smart moves vs. red flags, and how final decisions are made. The discussion also explores the potential, limitations, and ethical pitfalls. Moderator: Mattias Mandorfer Speakers: Tobias Böttler, Virginia Hernández-Gea, Josep Llovet All EASL Studio Podcasts are available on EASL Campus. Click here to see all... | 31m 11s | ||||||
| 11/6/25 |  EASL Studio Podcast: Are we finally entering an era of effective treatment for PSC? | After years of limited progress, recent trials hint at a changing landscape for primary sclerosing cholangitis (PSC). In this episode, experts review emerging data and explore whether we’re approaching a new era of effective treatment. How should clinicians assess these therapies, and could they shift the current management of PSC? Moderator: Debbie Shawcross Speakers: Cynthia Levy, Stephen Rossi, Michael Trauner All EASL Studio Podcasts are available on EASL Campus. Click here to see all EAS... | 42m 41s | ||||||
| 10/9/25 |  EASL Studio Podcast: Does it really matter whether we call it ACLF or acute decompensation? | This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or improves outcomes. A thought-provoking look at where terminology meets bedside care. Moderator: T... | 31m 23s | ||||||
| 10/2/25 |  EASL Studio Podcast: The Clinical Blind Spot: Are We Neglecting Alcohol? | This EASL Studio explores the discrepancy between the huge burden of patients hospitalised with, and dying from, alcohol-related liver disease (ALD) or MetALD, versus the same disease’s near non-existence from population data. The panel will discuss whether current classification systems (heavily favoring metabolic causes) misrepresent the true burden of ALD and MetALD, and what clinicians can do to better map the role of alcohol in liver patients. Moderator: Maja Thiele Speakers: Brian Lee, ... | 34m 59s | ||||||
| 9/25/25 |  EASL Studio Podcast: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025? | What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025? Moderator: Ahmed Elsharkawy Speakers: Ashley Brown, Tatyana... | 35m 41s | ||||||
| 9/18/25 |  EASL Studio Podcast: What Matters Most? The questions every hepatologist should ask their patients | In hepatology, effective care goes beyond diagnostics and treatment. This episode explores the crucial questions hepatologists should ask to truly understand their patients’ needs, values, and priorities. By focusing on communication and patient-centred care, our experts highlight how listening carefully can improve adherence, enhance quality of life, and ultimately lead to better outcomes. Moderator: Pierre-Emmanuel Rautou Speakers: Agnès Dumas, Maria Hjorth, José Willemse, Zobair Younossi A... | 33m 17s | ||||||
| 6/27/25 |  EASL DeepDive: Diagnosis, non-invasive screening and risk stratification of MASLD cases | This first session in a two-part EASL DeepDive series on the 2024 EASL-EASD-EASO MASLD Clinical Practice Guidelines will provide a detailed examination of the recommendations concerning diagnosis, non-invasive assessment, and risk stratification, with a view to supporting evidence-based clinical practice. Learning objectives Have a good understanding of the concept/definition of MASLD within the framework of the new SLD nomenclature, including its contribution to disease progression in other ... | 1h 06m 33s | ||||||
| 6/19/25 |  EASL Studio Podcast: EASL CPGs on Vascular Liver Diseases: What’s New? | This episode addresses key challenges in vascular complications of liver disease, including the management of portal vein thrombosis (PVT) in patients with and without cirrhosis. Experts will explore controversies surrounding long-term anticoagulation therapy and discuss insights from the CIRROXABAN paper. Additionally, the episode will shed light on the management of splanchnic artery aneurysms, offering valuable guidance for clinical practice. Moderator: Pierre-Emmanuel Rautou; Facult... | 32m 32s | ||||||
Showing 25 of 152
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
17 placements across 16 markets.
Chart Positions
17 placements across 16 markets.